Direct Reprogramming of Somatic Cells to Neural Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for reprogramming somatic cells into induced pluripotent stem cells (iPS cells) face challenges such as high risk of neoplastic transformation due to viral vector integration, low efficiency, and the ability to differentiate into unwanted cell types, including teratomas, which pose ethical and therapeutic concerns.
Innovation Solution
The method involves reprogramming somatic cells directly into induced neural stem cells (iNS cells) using the transcription factors Sox2 and c-Myc, bypassing the iPS cell stage, which reduces the risk of neoplastic transformation and enhances differentiation efficiency into specific neural cell types like glial cells and neurons, without the ability to form teratomas.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If somatic cells are reprogrammed to iPS cells using viral vectors and multiple transcription factors, then pluripotency is achieved, but the risk of neoplastic transformation increases due to viral integration and oncogene activation
Solution Approach 1:
The invention extracts and removes the harmful elements (viral vectors and multiple transcription factors including oncogenes) from the reprogramming process. By using only two safe transcription factors (Sox2 and c-Myc) without viral integration, the method eliminates the risk of insertional mutagenesis and teratoma formation while still achieving neural stem cell reprogramming
Solution Approach 2:
The invention converts the potential harm of c-Myc oncogene into a beneficial tool by using it in controlled combination with Sox2 for direct neural stem cell reprogramming. The c-Myc gene, normally associated with cancer risk, is utilized here to enhance reprogramming efficiency while the direct differentiation path prevents teratoma formation
2Productivity
If viral vectors are used for reprogramming, then reprogramming efficiency is achieved, but the complexity of the procedure and risk of genomic integration increase
Solution Approach 1:
The invention removes viral vectors from the reprogramming system, replacing them with simple plasmid-based or protein-based delivery of transcription factors. This extraction of harmful complexity maintains reprogramming efficiency while eliminating the need for viral production, integration, and safety monitoring procedures
Solution Approach 2:
The invention changes the delivery parameters from viral integration to transient expression. By using plasmids or proteins that do not integrate into the genome, the method maintains high reprogramming efficiency through sufficient transient factor expression while dramatically simplifying the overall procedure and eliminating long-term safety concerns
3Reliability
If reprogramming proceeds through the iPS cell stage, then pluripotency is achieved, but the time required and risk of unwanted differentiation increase
Solution Approach 1:
The invention performs preliminary action by directly establishing neural stem cell characteristics during reprogramming, rather than first creating pluripotent cells and then differentiating them. The transcription factor combination and culture conditions are designed from the start to guide cells directly toward neural stem cell fate, bypassing the time-consuming iPS intermediate stage
Solution Approach 2:
The invention skips the iPS cell stage entirely in the reprogramming pathway. By using Sox2 and c-Myc in a direct reprogramming protocol with neural-specific culture conditions, the method rushes through the intermediate pluripotent stage and directly generates neural stem cells, reducing both time and the risk of unwanted cell type formation
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
The present invention concerns the neural stem cell (iNS) that is characterized by an expression of Sox2, GFAP, and nestin markers. The methods for somatic cell reprogramming with one reprogramming factor or two reprogramming factors were also disclosed.